IL6ST
Interleukin-6 receptor subunit beta
As of the edition of 20 October 2026, IL6ST (interleukin-6 receptor subunit beta, UniProt P40189) has 1 drug tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P40189
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 20
- Disease areas
- Immune system; Nervous system; Eye; Inherited and neonatal; Hormones; Bones, joints and muscles; Cancer; Heart and blood vessels
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Satralizumab | Marketed | Phase 4 | Ends 2032 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |